CSIMarket
 


Regenerx Biopharmaceuticals inc   (RGRX)
Other Ticker:  
 
 

RGRX's Net Income Growth by Quarter and Year

Regenerx Biopharmaceuticals Inc 's Net Income results by quarter and year




RGRX Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -0.39 -0.45 -0.37
III Quarter September - -0.37 -0.43 -0.33
II Quarter June - -0.55 -0.34 -0.44
I Quarter March -0.39 -0.42 -0.38 -0.39
FY   -0.39 -1.73 -1.60 -1.53



RGRX Net Income first quarter 2023 Y/Y Growth Comment
Regenerx Biopharmaceuticals inc in the first quarter 2023 recorded net loss of $ -0.39 millions.

According to the results reported in the first quarter 2023, Regenerx Biopharmaceuticals Inc achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Regenerx Biopharmaceuticals Inc ' s Net Income no change of % ranks overall at the positon no. in the first quarter 2023.




RGRX Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Regenerx Biopharmaceuticals Inc 's first quarter 2023 Net Income $ -0.39 millions RGRX's Income Statement
Regenerx Biopharmaceuticals Inc 's first quarter 2022 Net Income $ -0.42 millions Quarterly RGRX's Income Statement
New: More RGRX's historic Net Income Growth >>


RGRX Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Regenerx Biopharmaceuticals Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RGRX's I. Quarter Q/Q Net Income Comment
I. Quarter 2023 accomplishment of -0.39 millions by Regenerx Biopharmaceuticals inc come out even more unfavourable compare to the net loss -0.39 millions a quarter before.

Within Major Pharmaceutical Preparations industry Regenerx Biopharmaceuticals inc achieved highest sequential Net Income growth. While Regenerx Biopharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is .


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RGRX's I. Quarter Q/Q Net Income Comment
Current net loss of -0.39 millions by Regenerx Biopharmaceuticals inc come out even less good if you take a look at net loss -0.39 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Regenerx Biopharmaceuticals inc achieved highest sequential Net Income growth. While Regenerx Biopharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is .


Regenerx Biopharmaceuticals Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
Cumulative Net Income 12 Months Ending $ -1.69 $ -1.73 $ -1.79 $ -1.85 $ -1.64
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Regenerx Biopharmaceuticals Inc ' has realized cumulative trailing twelve months net loss of $ -2 millions in the Mar 31 2023 period.

Regenerx Biopharmaceuticals inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Regenerx Biopharmaceuticals Inc ' has realized cumulative trailing twelve months net loss of $ -2 millions in the Mar 31 2023 period.

Regenerx Biopharmaceuticals inc achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
RGRX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for RGRX's Competitors
Net Income Growth for Regenerx Biopharmaceuticals Inc 's Suppliers
Net Income Growth for RGRX's Customers

You may also want to know
RGRX's Annual Growth Rates RGRX's Profitability Ratios RGRX's Asset Turnover Ratio RGRX's Dividend Growth
RGRX's Roe RGRX's Valuation Ratios RGRX's Financial Strength Ratios RGRX's Dividend Payout Ratio
RGRX's Roa RGRX's Inventory Turnover Ratio RGRX's Growth Rates RGRX's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2023
Intuitive Surgical Inc -2.33%$ -2.328 millions
U S Physical Therapy Inc-4.63%$ -4.632 millions
Zoetis Inc -7.24%$ -7.239 millions
Innoviva Inc -7.91%$ -7.906 millions
Vertex Pharmaceuticals Inc-8.17%$ -8.175 millions
Edwards Lifesciences Corporation-8.86%$ -8.860 millions
Lifevantage Corp-10.43%$ -10.429 millions
Iqvia Holdings Inc -11.08%$ -11.077 millions
Viemed Healthcare Inc -13.90%$ -13.905 millions
Insulet Corporation-14.39%$ -14.388 millions
Chemed Corporation-15.66%$ -15.659 millions
Regeneron Pharmaceuticals Inc -15.99%$ -15.994 millions
Davita Inc -17.04%$ -17.038 millions
National Research Corporation-18.44%$ -18.445 millions
West Pharmaceutical Services Inc -19.45%$ -19.448 millions
Amedisys Inc -21.45%$ -21.455 millions
Dariohealth Corp -21.64%$ -21.641 millions
Biomx Inc -22.13%$ -22.132 millions
3m Company-24.71%$ -24.712 millions
Integra Lifesciences Holdings Corp-26.37%$ -26.367 millions
National Healthcare Corp-26.48%$ -26.477 millions
Eli Lilly And Company-29.32%$ -29.324 millions
Pacific Health Care Organization Inc -30.46%$ -30.459 millions
Corcept Therapeutics Inc-30.66%$ -30.662 millions
Synaptogenix Inc -31.54%$ -31.544 millions
Supernus Pharmaceuticals inc -33.84%$ -33.838 millions
Halozyme Therapeutics Inc -34.09%$ -34.094 millions
Merck and Co Inc -34.50%$ -34.500 millions
Align Technology inc -34.62%$ -34.624 millions
Avantor Inc -36.19%$ -36.187 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com